PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Study sponsor: Mesoblast, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2009-03-09Actual
Enrollment · participants62Actual
Source updated2026-03-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.